INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 52 filers reported holding INOZYME PHARMA INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,334,112 | -19.9% | 1,270,027 | +6.3% | 2.11% | +4.7% |
| Q2 2023 | $6,656,301 | -13.5% | 1,195,027 | -11.0% | 2.02% | -1.1% |
| Q1 2023 | $7,690,754 | +232.2% | 1,342,191 | -39.1% | 2.04% | +231.0% |
| Q4 2022 | $2,315,120 | -56.7% | 2,204,876 | +10.4% | 0.62% | -57.1% |
| Q3 2022 | $5,350,000 | -44.9% | 1,996,277 | -1.8% | 1.44% | -61.2% |
| Q2 2022 | $9,701,000 | +165.9% | 2,033,802 | +128.0% | 3.70% | +138.7% |
| Q1 2022 | $3,649,000 | -40.0% | 892,057 | 0.0% | 1.55% | -23.1% |
| Q4 2021 | $6,084,000 | -43.0% | 892,057 | -3.1% | 2.02% | -35.1% |
| Q3 2021 | $10,666,000 | -32.5% | 920,264 | -0.8% | 3.11% | -15.3% |
| Q2 2021 | $15,801,000 | -13.9% | 927,264 | 0.0% | 3.68% | 0.0% |
| Q1 2021 | $18,360,000 | -10.6% | 927,264 | -6.8% | 3.68% | -36.5% |
| Q4 2020 | $20,545,000 | -22.6% | 995,396 | -1.4% | 5.79% | -38.7% |
| Q3 2020 | $26,529,000 | – | 1,009,117 | – | 9.44% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 4,494,851 | $18,878,374 | 7.53% |
| CHI Advisors LLC | 1,270,027 | $5,334,112 | 2.11% |
| Samsara BioCapital, LLC | 1,562,500 | $6,562,500 | 2.01% |
| Affinity Asset Advisors, LLC | 1,379,852 | $5,795,378 | 1.63% |
| Sofinnova Investments, Inc. | 4,280,308 | $17,977,294 | 1.13% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,234,907 | $5,186,609 | 0.94% |
| Octagon Capital Advisors LP | 1,300,000 | $5,460,000 | 0.84% |
| NEA Management Company, LLC | 2,437,689 | $10,238,294 | 0.79% |
| Knott David M Jr | 454,008 | $1,907 | 0.73% |
| Rock Springs Capital Management LP | 3,681,174 | $15,460,931 | 0.41% |